Circumferential and focal ablation of Barrett's esophagus containing dysplasia

Virender K. Sharma, H. Jae Kim, Ananya Das, Christopher D. Wells, Cuong C Nguyen, David E. Fleischer

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

OBJECTIVES: Dysplasia in a Barrett's esophagus (BE) is associated with an increased risk for developing esophageal adenocarcinoma. Ablation using the HALO system has shown promise for the treatment of BE with dysplasia. The objective of this study was to assess the safety and efficacy of a stepwise regimen of circumferential and focal ablation using the HALO system for the treatment of BE with dysplasia. METHODS: BE patients with low-grade dysplasia (LGD) or high-grade dysplasia (HGD) were enrolled. Primary circumferential ablation was followed every 3 months by further circumferential ablation or focal ablation until complete endoscopic eradication of BE was achieved. At 3- or 6-month intervals, depending on baseline grade, targeted and four quadrant random biopsies were obtained to assess the histological response to ablation. A complete response (CR) is defined as all biopsies negative for intestinal metaplasia (IM) (CR-IM) or dysplasia (CR-D) at last available follow-up. RESULTS: A total of 63 patients were treated (57 men; median age 71 years; median BE length 5 cm), with worst grade of dysplasia being LGD (n=39) and HGD (n=24). Follow-up is available for 62 patients (median 24 months). Overall, CR-IM is 79% and CR-D is 89%. For the LGD cohort, CR-IM is 87% and CR-D is 95%. For the HGD cohort, CR-IM is 67% and CR-D is 79%. CONCLUSIONS: Stepwise circumferential and focal ablation of BE containing dysplasia appears to be a safe and effective intervention, achieving a CR for dysplasia in 95% and 79% of LGD and HGD patients, respectively.

Original languageEnglish (US)
Pages (from-to)310-317
Number of pages8
JournalAmerican Journal of Gastroenterology
Volume104
Issue number2
DOIs
StatePublished - Feb 2009

Fingerprint

Barrett Esophagus
Metaplasia
Biopsy
Adenocarcinoma
Safety
Therapeutics

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Circumferential and focal ablation of Barrett's esophagus containing dysplasia. / Sharma, Virender K.; Jae Kim, H.; Das, Ananya; Wells, Christopher D.; Nguyen, Cuong C; Fleischer, David E.

In: American Journal of Gastroenterology, Vol. 104, No. 2, 02.2009, p. 310-317.

Research output: Contribution to journalArticle

Sharma, Virender K. ; Jae Kim, H. ; Das, Ananya ; Wells, Christopher D. ; Nguyen, Cuong C ; Fleischer, David E. / Circumferential and focal ablation of Barrett's esophagus containing dysplasia. In: American Journal of Gastroenterology. 2009 ; Vol. 104, No. 2. pp. 310-317.
@article{81401d7675644d9197cb3e6fbe95fdf0,
title = "Circumferential and focal ablation of Barrett's esophagus containing dysplasia",
abstract = "OBJECTIVES: Dysplasia in a Barrett's esophagus (BE) is associated with an increased risk for developing esophageal adenocarcinoma. Ablation using the HALO system has shown promise for the treatment of BE with dysplasia. The objective of this study was to assess the safety and efficacy of a stepwise regimen of circumferential and focal ablation using the HALO system for the treatment of BE with dysplasia. METHODS: BE patients with low-grade dysplasia (LGD) or high-grade dysplasia (HGD) were enrolled. Primary circumferential ablation was followed every 3 months by further circumferential ablation or focal ablation until complete endoscopic eradication of BE was achieved. At 3- or 6-month intervals, depending on baseline grade, targeted and four quadrant random biopsies were obtained to assess the histological response to ablation. A complete response (CR) is defined as all biopsies negative for intestinal metaplasia (IM) (CR-IM) or dysplasia (CR-D) at last available follow-up. RESULTS: A total of 63 patients were treated (57 men; median age 71 years; median BE length 5 cm), with worst grade of dysplasia being LGD (n=39) and HGD (n=24). Follow-up is available for 62 patients (median 24 months). Overall, CR-IM is 79{\%} and CR-D is 89{\%}. For the LGD cohort, CR-IM is 87{\%} and CR-D is 95{\%}. For the HGD cohort, CR-IM is 67{\%} and CR-D is 79{\%}. CONCLUSIONS: Stepwise circumferential and focal ablation of BE containing dysplasia appears to be a safe and effective intervention, achieving a CR for dysplasia in 95{\%} and 79{\%} of LGD and HGD patients, respectively.",
author = "Sharma, {Virender K.} and {Jae Kim}, H. and Ananya Das and Wells, {Christopher D.} and Nguyen, {Cuong C} and Fleischer, {David E.}",
year = "2009",
month = "2",
doi = "10.1038/ajg.2008.142",
language = "English (US)",
volume = "104",
pages = "310--317",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Circumferential and focal ablation of Barrett's esophagus containing dysplasia

AU - Sharma, Virender K.

AU - Jae Kim, H.

AU - Das, Ananya

AU - Wells, Christopher D.

AU - Nguyen, Cuong C

AU - Fleischer, David E.

PY - 2009/2

Y1 - 2009/2

N2 - OBJECTIVES: Dysplasia in a Barrett's esophagus (BE) is associated with an increased risk for developing esophageal adenocarcinoma. Ablation using the HALO system has shown promise for the treatment of BE with dysplasia. The objective of this study was to assess the safety and efficacy of a stepwise regimen of circumferential and focal ablation using the HALO system for the treatment of BE with dysplasia. METHODS: BE patients with low-grade dysplasia (LGD) or high-grade dysplasia (HGD) were enrolled. Primary circumferential ablation was followed every 3 months by further circumferential ablation or focal ablation until complete endoscopic eradication of BE was achieved. At 3- or 6-month intervals, depending on baseline grade, targeted and four quadrant random biopsies were obtained to assess the histological response to ablation. A complete response (CR) is defined as all biopsies negative for intestinal metaplasia (IM) (CR-IM) or dysplasia (CR-D) at last available follow-up. RESULTS: A total of 63 patients were treated (57 men; median age 71 years; median BE length 5 cm), with worst grade of dysplasia being LGD (n=39) and HGD (n=24). Follow-up is available for 62 patients (median 24 months). Overall, CR-IM is 79% and CR-D is 89%. For the LGD cohort, CR-IM is 87% and CR-D is 95%. For the HGD cohort, CR-IM is 67% and CR-D is 79%. CONCLUSIONS: Stepwise circumferential and focal ablation of BE containing dysplasia appears to be a safe and effective intervention, achieving a CR for dysplasia in 95% and 79% of LGD and HGD patients, respectively.

AB - OBJECTIVES: Dysplasia in a Barrett's esophagus (BE) is associated with an increased risk for developing esophageal adenocarcinoma. Ablation using the HALO system has shown promise for the treatment of BE with dysplasia. The objective of this study was to assess the safety and efficacy of a stepwise regimen of circumferential and focal ablation using the HALO system for the treatment of BE with dysplasia. METHODS: BE patients with low-grade dysplasia (LGD) or high-grade dysplasia (HGD) were enrolled. Primary circumferential ablation was followed every 3 months by further circumferential ablation or focal ablation until complete endoscopic eradication of BE was achieved. At 3- or 6-month intervals, depending on baseline grade, targeted and four quadrant random biopsies were obtained to assess the histological response to ablation. A complete response (CR) is defined as all biopsies negative for intestinal metaplasia (IM) (CR-IM) or dysplasia (CR-D) at last available follow-up. RESULTS: A total of 63 patients were treated (57 men; median age 71 years; median BE length 5 cm), with worst grade of dysplasia being LGD (n=39) and HGD (n=24). Follow-up is available for 62 patients (median 24 months). Overall, CR-IM is 79% and CR-D is 89%. For the LGD cohort, CR-IM is 87% and CR-D is 95%. For the HGD cohort, CR-IM is 67% and CR-D is 79%. CONCLUSIONS: Stepwise circumferential and focal ablation of BE containing dysplasia appears to be a safe and effective intervention, achieving a CR for dysplasia in 95% and 79% of LGD and HGD patients, respectively.

UR - http://www.scopus.com/inward/record.url?scp=59749094369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59749094369&partnerID=8YFLogxK

U2 - 10.1038/ajg.2008.142

DO - 10.1038/ajg.2008.142

M3 - Article

C2 - 19174783

AN - SCOPUS:59749094369

VL - 104

SP - 310

EP - 317

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 2

ER -